Taro Pharmaceutical Industries Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Taro Pharmaceutical Industries Stock Forecast and Price Target
According to esteemed experts, the average price target for Taro Pharmaceutical Industries to reach this year is $43.00, with a potential upside of approximately 1.22%. This prediction is based on a high estimate of $43.00 and a low estimate of $43.00. If you're looking for Taro Pharmaceutical Industries (TARO) stock information, you might also want to check out Viatris Inc (NasdaqGS:VTRS).
1.22% Upside
Taro Pharmaceutical Industries Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Taro Pharmaceutical Industries's Price has gone down from $67.31 to $0.00 – a 100.00% drop. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach $0.00 – an increase of 100.00%. The Taro Pharmaceutical Industries forecast is for Fair Value to reach $0.00 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF90.00 | Buy/Sell | CHF105.00 | 19.58% |
| ALC Stock Forecast | Alcon | Outperform |
8
|
CHF71.56 | Buy/Sell | CHF90.64 | 34.66% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.47 | Buy/Sell | $11.73 | 4.62% |
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£18.54 | Buy/Sell | £28.11 | 57.55% |
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$31.27 | Buy/Sell | $44.75 | 26.64% |
Taro Pharmaceutical Industries Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Taro Pharmaceutical Industries's Revenue has gone down from $644.77M to $572.95M – a 11.14% drop. In the next year, analysts are expecting an increase in Revenue, predicting it will reach $598.20M – an increase of 4.41%. The Taro Pharmaceutical Industries forecast is for Revenue to reach $579.67M or grow by 1.17%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PBH Stock Forecast | Prestige Consumer Healthcare | Outperform |
16
|
$70.14 | Buy/Sell | $71.50 | 6.22% |
| BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$8.62 | Buy/Sell | $9.50 | 10.21% |
| AMRX Stock Forecast | Amneal Pharmaceuticals | Outperform |
16
|
$5.90 | Buy/Sell | $6.13 | 27.12% |
.jpg)
Taro Pharmaceutical Industries EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Taro Pharmaceutical Industries's EBITDA has decreased by 81.40%, going from $267.92M to $49.84M. The next year looks promising for Taro Pharmaceutical Industries, with analysts predicting EBITDA of $95.24M – an increase of 91.08%. Over the next seven years, experts anticipate that Taro Pharmaceutical Industries's EBITDA will grow at a rate of 232.97%.
Taro Pharmaceutical Industries EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Taro Pharmaceutical Industries's EBIT has decreased from $246.54M to $17.71M – a 92.82% drop. For the next year, analysts are expecting EBIT to reach $58.53M – an increase of 230.47%. Over the next seven years, experts predict that EBIT will grow by 1939.70%.
Taro Pharmaceutical Industries EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Taro Pharmaceutical Industries's EPS has gone down from $6.35 to $0.00 – a 100.00% drop. In the next year, analysts are expecting an increase in EPS, predicting it will reach $0.00 – an increase of 100.00%. The Taro Pharmaceutical Industries forecast is for EPS to reach $0.00 or grow by 100.00%.
Site Navigation
.jpg)